Eldecalcitol

Drug profile

Key facts

Eldecalcitol is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2011. DrugCentral lists 2 molecular targets, including Vdr and VDR. Recorded indications include Osteoporosis.

• Molecular targets: Vdr and VDR (2 listed in DrugCentral).
• Indications: Osteoporosis.
• Molecular formula: C30H50O5; molecular weight 490.73 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Osteoporosis

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Vitamin D3 receptor	Vdr	agonist	Kd 8.00
Vitamin D3 receptor	VDR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2011-01-21	PMDA	—	Chugai Pharmaceutical Co., Ltd

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Renal impairment	297.9
Osteonecrosis of jaw	296.3
Hypercalcaemia	288.7
Interstitial lung disease	195.3
Femoral neck fracture	147.2
Cerebral infarction	137.9
Spinal compression fracture	136.1
Fall	130.7
Milk-alkali syndrome	109.1
Hepatic function abnormal	107.8
Hypocalcaemia	99.2
Femur fracture	95.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Eldecalcitol is on its molecule page.

• Molecular formula: C₃₀H₅₀O₅
• Molecular weight: 490.73 g/mol
• CAS number: 104121-92-8
• InChIKey: FZEXGDDBXLBRTD-AYIMTCTASA-N
• PubChem CID: 6918141

C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eldecalcitol used for?

DrugCentral lists the following indications for Eldecalcitol: Osteoporosis.

How does Eldecalcitol work?

Its molecular targets in DrugCentral include Vdr (agonist) and VDR (agonist).

When was Eldecalcitol first approved?

Eldecalcitol was first approved by the PMDA in 2011.

What is the chemical formula of Eldecalcitol?

Eldecalcitol has the molecular formula C30H50O5 and a molecular weight of 490.73 g/mol.

Sources

• DrugCentral drug card 5169 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297608 — compound record and bioactivity
• PubChem CID 6918141 — chemical identifiers
• DrugBank DB05295 — drug record
• FDA UNII I2JP8UE90H — substance identity
• UniProt P11473 (VDR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.